HLIB Research

PP 9484/12/2012 (031413)

Nazira Abdullah <u>Nurul Nazira@hlib.hongleong.com.my</u> (603) 2083 1717

BUY (Maintain)

Target Price:	RM2.12
Previously:	RM2.11
Current Price:	RM1.80
Capital upside	17.8%
Dividend yield	6.1%
Expected total return	23.9%

Sector coverage: Property

Company description: Matrix involves in property development and construction businesses primarily focus in Negeri Sembilan and Johor.

Share price



Stock information

MCH MK
5236
834
1,502
466
Yes
Yes

Major shareholders

15.1%
12.7%
10.0%

Earnings summary

FYE (Mar)	FY20	FY21f	FY22f
PATMI - core (RM m)	238.5	228.4	259.4
EPS - core (sen)	26.7	25.6	29.0
P/E (x) - FD	6.7	7.0	6.2

Matrix Concepts Holdings

A healthy showing

Matrix's 9MFY21 core PATMI of RM181.5m (+1.6% YoY) was above our and consensus expectation. The improved progressive earnings recognition in 9MFY21 is largely attributed to expedited construction progress and higher new property sales. 9MFY21 sales of RM865m (79% of full year target) was recoded while launches worth RM420m were carried out. We increase our forecast by 10.6%/2.2%/1.9% for FY21/22/23 to account for higher progressive billings recognitions and higher sales. Maintain BUY with a marginally higher TP of RM2.12 (from RM2.11) based on 35% discount to RNAV of RM3.27.

Above expectations. Matrix reported 3QFY21 core PATMI of RM75.3m (+0.4% QoQ, 15.3% YoY), bringing 9MFY21's sum to RM181.5m (+1.6% YoY). The results were above expectations forming 87% of our and consensus full year forecasts, attributable to expedited construction progress and higher new property sales.

Dividend. Declared third interim dividend of 3.0 (3QFY20: 3.0) sen per share going ex on 24 Mar 2021, bringing 9MFY21 dividends to 8 sen per share.

QoQ. Top line increased by 20.4% attributable to higher progress billing recognition in addition to higher sales. Nonetheless, core PATAMI was flattish (+0.4%) on the back of higher COGS (+60.3%) and higher other expenses (+42.9%).

YoY. Revenue rose by 13.1% on the back of improved progress billing recognition. Notwithstanding the lower gross profit by 4.2% from lower margin products, Matrix's core earnings increased by 15.3% thanks to reduced administrative and general expenses as well as higher share of results from the its JV-co in Indonesia.

YTD. Core earnings fell by 8.7% largely due to the loss of operations during the MCO period in 1QFY21 (impacted Apr month) but this was partially mitigated by lower selling and marketing expenses as well as administrative expenses. In turn, core earnings were flattish (1.6%).

Strong sales recorded. 3QFY21 new sales came in at RM263m, bringing 9MFY21 sales to RM865m which represents 79% of the full year target (RM1.1bn). With regards to launches, 3QFY21 launched RM420m worth of products bringing 9MFY21 launches to RM773.2m.

Outlook. For 4Q21, management is targeting to launch RM252.4m worth of GDV coming from Tiara Sendayan 7, Nusari Bayu 2 and Laman Sendayan 3. We believe Matrix's FY21 sales target of RM1.1bn (+6% YoY vs FY20) is achievable (despite the pandemic) given the encouraging response in recent quarter (81.9% take up rate in 3Q21 achieved). Earnings visibility will continue to be supported by new sales and unbilled sales of 0.8x cover (RM963m). In terms of dividend, we projected Matrix to be able to pay at least 11 sen per share for FY21 (40% dividend payout ratio) which translates to a yield of 6.1%. Furthermore, Matrix's healthy balance sheet of 0.04x net gearing (3Q21) will provide the buffer to sustain through this challenging environment.

Forecast. We increase our forecast by 10.6%/2.2%/1.9% for FY21-23 to account for higher progressive billings recognitions and higher sales.

Maintain **BUY** with a marginally higher TP of **RM2.12** (from RM2.11) based on 35% discount to RNAV of RM3.27 as we make changes to our earnings base. We continue to like Matrix as it is well-positioned to ride on affordable housing theme within its successful townships with cheap land cost and sustained property sales. This is supported by an attractive dividend yield of 6.1% for FY21 and 7.0% for FY22, being one of the highest in the sector.

Financial Forecast

All items in (RM m) unless otherwise stated

Balance Sheet

FYE Mar	FY19	FY20	FY21f	FY22f	FY23f
Cash	264.2	281.0	735.5	598.6	685.0
Receivables	425.0	533.0	395.5	509.3	538.1
Inventories	671.4	624.1	565.0	727.5	768.7
Others	749.2	1,138.7	896.5	1,014.4	1,041.5
Assets	2,109.9	2,576.9	2,592.6	2,849.8	3,033.2
Payables	381.6	484.5	367.3	472.9	499.6
Debt	362.3	427.6	427.6	427.6	427.6
Others	26.0	61.8	61.8	61.8	61.8
Liabilities	770.0	973.9	856.6	962.2	989.0
Shareholder's equity	1.327.1	1.605.1	1.742.2	1.897.8	2.058.7
Minority interest	0.8	(2.1)	(6.2)	(10.3)	(14.4)
Equity	1,327.9	1,603.0	1,736.0	1,887.5	2,044.3

Cash Flow Statement

FYE Mar FY19 FY20 FY21f FY	22f FY23f
Profit before taxation 301.8 337.6 306.0 34	8.3 360.1
D&A 10.5 11.7 11.1 1	0.9 10.7
Working capital (148.4) (165.5) 317.4 (29	2.5) (74.1)
Taxation (89.7) (100.1) (81.7) (9	3.0) (96.2)
Others 3.6 (31.3) -	0.0 (0.0)
CFO 77.9 52.4 552.8 (2	6.3) 200.6
Capex (32.1) (7.0) (7.0)	7.0) (7.0)
Others 19.4 (101.6) -	
CFI (12.8) (108.5) (7.0) (7.0) (7.0)
Changes in debt 29.2 57.8 -	
Shares issued 3.5 178.3 -	
Dividends (101.5) (97.5) (91.4) (10	3.8) (107.2)
Others (0.0)	0.0 (0.0)
CFF (68.8) 138.5 (91.4) (10	3.8) (107.2)
Net cash flow (3.7) 82.4 454.5 (13	7.0) 86.4
(,)	7.0) 60.4
Forex - 14.9 -	
Others 80.5	
5 5	5.5 598.6
Ending cash 264.2 281.0 735.5 59	8.6 685.0

HLIB Research

Income statement

FYE Mar	FY19	FY20	FY21f	FY22f	FY23f
Revenue	1045.5	1283.4	1031.1	1327.7	1402.8
Operating cost	(733.9)	(931.9)	(721.9)	(979.7)	(1042.6)
EBITDA	311.6	351.5	309.3	348.0	360.3
D&A	(10.5)	(11.7)	(11.1)	(10.9)	(10.7)
Net Interest	(3.3)	(2.1)	7.8	11.2	10.6
Pretax profit	301.8	337.6	306.0	348.3	360.1
Taxation	(79.5)	(103.2)	(81.7)	(93.0)	(96.2)
Minority Interest	(4.1)	(4.1)	(4.1)	(4.1)	(4.1)
PATAMI	226.3	238.5	228.4	259.4	268.1
Exceptionals	0.0	0.0	0.0	0.0	0.0
Core Earning	226.3	238.5	228.4	259.4	268.1
Basic shares (m)	829.2	829.2	829.2	829.2	829.2
Diluted shares (m)	893.1	893.1	893.1	893.1	893.1
Consensus core PATMI			208.5	240.8	253.5
HLIB/ Consensus			110%	108%	106%

Valuation ratios

Valuation ratios					
FYE Mar	FY19	FY20	FY21f	FY22f	FY23f
Net DPS (sen)	12.8	12.9	11.0	12.5	12.9
Yield (%)	7.1	7.2	6.1	7.0	7.2
Core EPS (sen)	27.3	28.8	27.5	31.3	32.3
Fully Diluted EPS (sen)	25.3	26.7	25.6	29.0	30.0
P/E (x)	6.6	6.3	6.5	5.8	5.6
FD P/E (x)	7.1	6.7	7.0	6.2	6.0
Market capitalization (m)	1492.5	1492.5	1492.5	1492.5	1492.5
Net cash (m)	(98.1)	(146.5)	308.0	171.0	257.4
Net gearing (%)	0.07	0.09	CASH	CASH	CASH
BV / share	1.6	1.9	2.1	2.3	2.5
P/BV (x)	1.1	0.9	0.9	0.8	0.7
ROA (%)	10.7	9.3	8.8	9.1	8.8
ROE (%)	17.0	14.9	13.2	13.7	13.1
Enterprise value	1590.6	1639.0	1184.5	1321.5	1235.1
EV/ EBITDA (x)	5.1	4.7	3.8	3.8	3.4

Margin ratios

FYE Mar	FY19	FY20	FY21f	FY22f	FY23f
EBITDA Margin	29.8	27.4	30.0	26.2	25.7
PBT Margin	28.9	26.3	29.7	26.2	25.7
PATMI	21.6	18.6	22.1	19.5	19.1

FYE March	3Q20	2Q21	3Q21	QoQ	YoY	9M20	9M21	YoY
Revenue	279.0	262.0	315.4	20.4%	13.1%	810.2	739.4	-8.7%
COGS	(123.2)	(118.5)	(166.2)	40.3%	35.0%	(389.5)	(361.7)	-7.1%
Gross Profit	155.8	143.5	149.2	3.9%	-4.2%	420.7	377.7	-10.2%
Other income	1.3	1.5	2.4	60.3%	92.3%	4.0	4.8	19.1%
Other expenses	(66.9)	(43.4)	(62.0)	42.9%	-7.3%	(184.3)	(149.5)	-18.9%
EBIT	90.1	101.6	89.6	-11.9%	-0.6%	240.4	233.0	-3.1%
Net Interest	1.3	1.0	0.9	-3.7%	-25.7%	3.4	2.9	-14.6%
PBT	91.4	102.6	94.5	-7.9%	3.5%	243.8	239.8	-1.6%
Tax	(26.0)	(29.1)	(20.5)	-29.5%	-21.1%	(65.2)	(62.5)	-4.1%
PAT	65.3	75.1	75.3	0.4%	15.3%	178.6	181.5	1.6%
EI (Gain/(Losses)	-	-	-	N.M.	N.M.	-	-	N.M.
Core PAT	65.3	75.1	75.3	0.4%	15.3%	178.6	181.5	1.6%
EBIT margin	32.3%	38.8%	28.4%	-10.4%	-3.9%	29.7%	31.5%	1.8%
PBT margin	32.7%	39.2%	30.0%	-9.2%	-2.8%	30.1%	32.4%	2.3%
PAT margin	23.4%	28.6%	23.9%	-4.8%	0.5%	22.0%	24.5%	2.5%

Company; HLIB

Figure #2 RNAV Table

	Stake	NPV
Projects	(%)	(RM m)
Bandar Sri Sendayan		
BSS	100%	863.5
BSI	100%	249.1
Others	100%	152.4
Australia	100%	22.4
Indonesia	30%	24.0
Total NPV		1,311.4
Shareholders funds	_	1,605.1
RNAV	_	2,916.5
Share base		893.1
RNAV/share		3.27
Discount		35%
Discounted RNAV/share		2.12

Company, HLIB

Disclaimer

The information contained in this report is based on data obtained from sources believed to be reliable. However, the data and/or sources have not been independently verified and as such, no representation, express or implied, are made as to the accuracy, adequacy, completeness or reliability of the info or opinions in the report.

Accordingly, neither Hong Leong Investment Bank Berhad nor any of its related companies and associates nor person connected to it accept any liability whatsoever for any direct, indirect or consequential losses (including loss of profits) or damages that may arise from the use or reliance on the info or opinions in this publication.

Any information, opinions or recommendations contained herein are subject to change at any time without prior notice. Hong Leong Investment Bank Berhad has no obligation to update its opinion or the information in this report.

Investors are advised to make their own independent evaluation of the info contained in this report and seek independent financial, legal or other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise represents a personal recommendation to you.

Under no circumstances should this report be considered as an offer to sell or a solicitation of any offer to buy any securities referred to herein.

Hong Leong Investment Bank Berhad and its related companies, their associates, directors, connected parties and/or employees may, from time to time, own, have positions or be materially interested in any securities mentioned herein or any securities related thereto, and may further act as market maker or have assumed underwriting commitment or deal with such securities and provide advisory, investment or other services for or do business with any companies or entities mentioned in this report. In reviewing the report, investors should be aware that any or all of the foregoing among other things, may give rise to real or potential conflict of interests.

This research report is being supplied to you on a strictly confidential basis solely for your information and is made strictly on the basis that it will remain confidential. All materials presented in this report, unless specifically indicated otherwise, are under copyright to Hong Leong Investment Bank Berhad. This research report and its contents may not be reproduced, stored in a retrieval system, redistributed, transmitted or passed on, directly or indirectly, to any person or published in whole or in part, or altered in any way, for any purpose.

This report may provide the addresses of, or contain hyperlinks to websites. Hong Leong Investment Bank Berhad takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to Hong Leong Investment Bank Berhad own website material) are provided solely for your convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or Hong Leong Investment Bank Berhad website shall be at your own risk.

1. As of 26 February 2021, Hong Leong Investment Bank Berhad has proprietary interest in the following securities covered in this report:
(a) -.

2. As of 26 February 2021, the analyst(s) whose name(s) appears on the front page, who prepared this report, has interest in the following securities covered in this report.

Published & printed by:

Hong Leong Investment Bank Berhad (10209-W)

Level 28, Menara Hong Leong, No. 6, Jalan Damanlela, Bukit Damansara, 50490 Kuala Lumpur Tel: (603) 2083 1800 Fax: (603) 2083 1766

Stock rating guide

BUY

Expected absolute return of +10% or more over the next 12 months.

HOLD

Expected absolute return of -10% to +10% over the next 12 months.

SELL

Expected absolute return of -10% or less over the next 12 months.

UNDER REVIEW Rating on the stock is temporarily under review which may or may not result in a change from the previous rating.

NOT RATED Stock is not or no longer within regular coverage.

Sector rating guide

OVERWEIGHT Sector expected to outperform the market over the next 12 months.

NEUTRAL Sector expected to perform in-line with the market over the next 12 months.

UNDERWEIGHT Sector expected to underperform the market over the next 12 months.

The stock rating guide as stipulated above serves as a guiding principle to stock ratings. However, apart from the abovementioned quantitative definitions, other qualitative measures and situational aspects will also be considered when arriving at the final stock rating. Stock rating may also be affected by the market capitalisation of the individual stock under review.